Drug Profile
Research programme: keratoconjunctivitis therapeutics - Adenovir Pharma
Alternative Names: APD-514; Epidemic keratoconjunctivitis therapeutics - Adenovir Pharma; Trisialic acid second generation drug - Adenovir PharmaLatest Information Update: 15 Nov 2019
Price :
$50
*
At a glance
- Originator Adenovir Pharma; Umea University
- Developer Adenovir Pharma
- Class Antivirals; Eye disorder therapies; Sialic acids
- Mechanism of Action Viral protein inhibitors; Virus attachment inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Infectious keratoconjunctivitis
Most Recent Events
- 01 Nov 2019 Discontinued - Preclinical for Infectious keratoconjunctivitis (Prevention) in Sweden (Ophthalmic)
- 01 Nov 2019 Discontinued - Preclinical for Infectious keratoconjunctivitis in Sweden (Ophthalmic)
- 29 Nov 2018 Adenovir Pharma has patent protection for plurality of the antiviral compound and its pharmaceutical composition in India